Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: microbiota

The Effects of IL-17A Inhibitors on the Microbiota

Vanessa Caceres  |  February 16, 2021

The use of an interleukin (IL) 17A inhibitor resulted in gut microbial dysbiosis and features of subclinical intestinal inflammation in a subgroup of psoriatic arthritis (PsA) and spondyloarthritis (SpA) patients, according to a multidisciplinary, collaborative study across several institutions published in Arthritis & Rheumatology.1 Understanding the downstream effects of these perturbations is an important step…

Filed under:Axial SpondyloarthritisConditionsPsoriatic ArthritisResearch Rheum Tagged with:gut microbiotaMicrobiomePsoriatic Arthritissecukinumab

Research Suggests Th17 Cells Have Microbiota-Dependent Role in RA

Kathy Holliman  |  March 18, 2019

A growing body of research is elucidating the role of intestinal microbiota in several auto­immune diseases, including rheumatoid arthritis (RA). Research published in December 2018 Arthritis & Rheumatology increases our understanding of the “extent and nature of mucosal immune activation during preclinical arthritis.”1 The research objective, according to the report, was to “dissect intestinal mucosal immune…

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:IL-17 CytokineMicrobiomeTh17

Gut Microbiota Directly Affects Inflammatory Arthritis

Lara C. Pullen, PhD  |  May 8, 2018

Gut microbiota may provide insight into important environmental triggers for autoimmune diseases. New research in mice indicates that intestinal dysbiosis triggers a mucosal immune response that stimulates T and B cells, which are critical to the development of inflammatory arthritis…

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:Arthritis & Rheumatologyenvironmentenvironmental factorgut microbiomegut microbiotaInflammatory arthritisRheumatoid Arthritis (RA)

Fungal Microbiota Dysbiosis Seen in Inflammatory Bowel Disease

Anne Harding  |  February 13, 2016

NEW YORK (Reuters Health)—Patients with inflammatory bowel disease (IBD) show imbalance in their fungal intestinal microbiota, according to new findings. “The fungal microbiota is a new actor to take into account in the pathogenesis of IBD and potentially in other diseases,” Dr. Harry Sokol of Hospital Saint-Antoine in Paris, an author of the new study,…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:Crohn's diseasefungalinflammatory bowel diseasemicrobiotaulcerative colitis

2014 ACR/ARHP Annual Meeting: Microbiota Power

Susan Bernstein  |  March 1, 2015

Gut bacteria may hold clues to breakthrough rheumatic disease treatments

Filed under:Meeting Reports Tagged with:ACR/ARHP Annual MeetingbacteriagutmicrobiotaRheumatic Disease

Reactive Arthritis: Chronic or Self-Limiting?

Michael J. Cammarata, MD  |  June 8, 2025

Reactive arthritis has proved to be a diagnostic & therapeutic challenge due to its diverse presentations.

Filed under:Axial SpondyloarthritisConditions Tagged with:biologic DMARDsdisease managementextra-articular manifestationsGlucocorticoidsHLA-B27infectious etiologymusculoskeletal manifestationsNSAIDsReactive arthritisspondyloarthritissulfasalazine

What Can I Eat or Not Eat to Cure My Arthritis?

Kim Arrey, DtP  |  April 7, 2025

“What can I eliminate from my diet to cure my arthritis?” is the question every client with arthritis asks me. Numerous case reports document patients who achieved lower markers of inflammation and reduced pain and stiffness associated with the removal of one or two food groups from a diet, but historically, no compelling evidence has…

Filed under:Conditions Tagged with:Dietgut microbiomegut microbiotaMediterranean dietnutrition

Insights into ACR Open Rheumatology

Leslie Mertz, PhD  |  February 28, 2025

ACR Open Rheumatology Editor-in-Chief Andras Perl, MD, PhD, discusses his unique career and his approach to balancing basic and translational research articles with outcome-focused articles within the journal.

Filed under:CareerEducation & TrainingOpinionProfiles Tagged with:ACR Open RheumatololgyAndras Perl

Key Research in Axial Spondyloarthritis Encapsulated

David S. Pisetsky, MD, PhD  |  December 2, 2024

Our understanding of (axSpA) has really changed, especially with regard to male-female differences. In this report, we identify important research on axSpA presented at ACR Convergence 2024, summarize the abstracts and comment on why each is important, addressing the relevance for clinicians and the potential impact on future research.

Filed under:ACR ConvergenceAxial SpondyloarthritisConditionsGuidanceMeeting Reports Tagged with:ACR Convergence 2024ACR Convergence 2024 axSpA

Approaches to Difficult-to-Manage Spondyloarthritis

Samantha C. Shapiro, MD  |  November 22, 2024

At this ACR Convergence 2024 session, two experts spoke about identifying difficult-to-manage patients with spondyloarthritis, differentiating active disease from fibromyalgia & therapy selection in these patients.

Filed under:ACR ConvergenceAxial SpondyloarthritisConditionsMeeting Reports Tagged with:ACR Convergence 2024ACR Convergence 2024 axSpA

  • 1
  • 2
  • 3
  • …
  • 7
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences